Journal: bioRxiv

Article Title: Genetic regulators of neuronal survival across metabolic environments

doi: 10.64898/2025.12.19.695350

Figure Lengend Snippet: A) Volcano plot of genes up- or down-regulated in KIAA1429 knockdown vs NTG control neurons. Glycolytic genes are more strongly affected than mitochondrial complex I assembly genes. Data compiled from n = 2 samples per condition. B) Plot of transcripts’ abundance in KIAA1429 KD cells and NTG control cells after 4-hour exposure to transcription inhibitor actinomycin relative to before exposure. Knockdown in KIAA1429 was associated with decreased abundance of SOX2 and NGF-related transcription targets (dark blue) after treatment with actinomycin. The expression of these transcripts was not significantly decreased in neuronal cells expressing a non-targeting guide, also subjected to treatment with actinomycin, indicating that KIAA1429 activity has a stabilizing effect on these transcripts. In contrast, glycolytic transcripts (red) significantly increased expression in neuronal cells with KIAA1429 knockdown and actinomycin treatment, indicating that stability of these transcripts was not impacted by KIAA1429 expression. Data compiled from n = 2 samples per condition. All “hit” genes have adjusted p-values < 0.05.

Article Snippet: Gene expression was measured by real-time PCR on QuantStudio 5 using FAM-MGB Taqman Gene Expression Assays (ThermoFisher, assay ID: Hs00198702_m1 GLO1 , Hs00936421_m1 KIAA1429 , Hs01556304_m1 TDRD3 , Hs00902194_m1 MAPT , Hs00175976_m1 HK1 , Hs00976715_m1 GPI , Hs01075411_m1 PFKM , Hs01378790_g1 LDHA , Hs00761782_s1 PKM , Hs01652468_g1 PGAM1 , Hs00361415_m1 ENO1 ) together with VIC-MGB human ACTB (ThermoFisher, #4326315E).

Techniques: Knockdown, Control, Expressing, Activity Assay

Journal: bioRxiv

Article Title: Genetic regulators of neuronal survival across metabolic environments

doi: 10.64898/2025.12.19.695350

Figure Lengend Snippet: A) Heatmap of the cluster of genes enriched for dendrite membrane components from includes MAPT , KIAA1429, and TDRD3 . Knockdown of these genes results in a common phenotype of poor survival in the high-oxygen glycolytic state (20G), while retaining survival in the high oxygen respiratory state (20R). B) Proposed mechanism by which knocking down genes that support various steps in late glycolysis results in diversion of glucose to upstream glycolytic branch metabolites, including nucleotides. C) Bubble plot of enriched metabolic pathways among metabolites with increased or decreased 13C-glucose derived labeling in neurons with genetic knockdowns. Bubble radius corresponds to pathway impact, which is a measure of the centrality of enriched metabolites. In the high-oxygen glycolytic state, knockdown of these three functionally similar genes in neuronal cells was associated with increased 13C-glucose-derived labeling across purine metabolites, compared to neuronal cells expressing a non-targeting sgRNA. In contrast, knockdown of GLO1 , a gene less related gene by hierarchical clustering, did not increase 13C-glucose-derived labeling in purine metabolites. D) UDP, AMP, and ADP metabolites specifically are significantly increased 13C-glucose-derived labeling associated with knockdown in MAPT , KIAA1429 , and TDRD3 but not GLO1 in the high-oxygen glycolytic state. E) TCA cycle metabolites are among the metabolites that have less 13C-glucose-derived labeling in the high-oxygen glycolytic state.

Article Snippet: Gene expression was measured by real-time PCR on QuantStudio 5 using FAM-MGB Taqman Gene Expression Assays (ThermoFisher, assay ID: Hs00198702_m1 GLO1 , Hs00936421_m1 KIAA1429 , Hs01556304_m1 TDRD3 , Hs00902194_m1 MAPT , Hs00175976_m1 HK1 , Hs00976715_m1 GPI , Hs01075411_m1 PFKM , Hs01378790_g1 LDHA , Hs00761782_s1 PKM , Hs01652468_g1 PGAM1 , Hs00361415_m1 ENO1 ) together with VIC-MGB human ACTB (ThermoFisher, #4326315E).

Techniques: Membrane, Knockdown, Derivative Assay, Labeling, Expressing

Journal: iScience

Article Title: KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability

doi: 10.1016/j.isci.2026.115198

Figure Lengend Snippet: Comprehensive analysis of the KIAA1429 in the TCGA and GEO database (A) The expression of KIAA1429 in the TCGA-KIRCC database (tumor samples n = 523, normal samples n = 100). (B–D) The expression levels of KIAA1429 in ccRCC tissues and adjacent normal tissues (23 pairs of paired samples) in (B) GSE36895 dataset, (C) GSE53757 dataset (72 pairs of paired samples), and (D) GSE40435 dataset (101 pairs of paired samples). (E) The GEPIA database analyzed the expression of KIAA1429 in patients with ccRCC of different clinical stages. (F and G) The GEPIA database analyzed the effect of KIAA1429 mRNA expression on the OS and DFS of patients with ccRCC. Data are presented as the means ± SEM. ∗ p < 0.05, ∗∗∗ p < 0.001 by Student’s two-tailed t test.

Article Snippet: KIAA1429 Rabbit Polyclonal antibody , Proteintech , Cat#24761-1-AP.

Techniques: Expressing, Two Tailed Test

Journal: iScience

Article Title: KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability

doi: 10.1016/j.isci.2026.115198

Figure Lengend Snippet: KIAA1429 mRNA and protein expression was significantly upregulated in ccRCC tissues and cell lines and its relationship to clinicopathological parameters (A and B) The protein and mRNA levels of KIAA1429 in ccRCC and normal kidney tissues. (C and D) KIAA1429 mRNA and protein expression in ccRCC cell lines and normal epithelium cell of renal tubule (HK2) cells. (E and F) The expression level of KIAA1429 in ccRCC tissue and surrounding normal renal tissue was detected using IHC. Scale bars, 100 μm. (G) The expression level of KIAA1429 in patients with ccRCC with different clinical stages and Fuhrman’s grade. (H) Effect of KIAA1429 expression on the overall survival of patients with ccRCC. T, tumor; N, normal. Data are presented as the means ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 by Student’s two-tailed t test.

Article Snippet: KIAA1429 Rabbit Polyclonal antibody , Proteintech , Cat#24761-1-AP.

Techniques: Expressing, Two Tailed Test

Journal: iScience

Article Title: KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability

doi: 10.1016/j.isci.2026.115198

Figure Lengend Snippet: KIAA1429 promoted ccRCC cell proliferation in vitro (A) Knockdown efficiencies of KIAA1429 mRNA in ACHN and Caki-1 cells were detected using RT-qPCR; KIAA1429 protein expression decreased significantly in groups of shKIAA1429 in western blot analysis. (B and C) The effect of KIAA1429 knockdown on the proliferation of ccRCC cells was detected using a CCK-8 assay (B) and colony formation assay (C). (D) The effect of KIAA1429 on the cell cycle of ccRCC cells was detected using flow cytometry. Data are presented as the means ± SEM ∗ p < 0.05, ∗∗ p < 0.01 by Student’s two-tailed t test.

Article Snippet: KIAA1429 Rabbit Polyclonal antibody , Proteintech , Cat#24761-1-AP.

Techniques: In Vitro, Knockdown, Quantitative RT-PCR, Expressing, Western Blot, CCK-8 Assay, Colony Assay, Flow Cytometry, Two Tailed Test

Journal: iScience

Article Title: KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability

doi: 10.1016/j.isci.2026.115198

Figure Lengend Snippet: KIAA1429 promoted ccRCC cell migration and invasion in vitro (A and B) The effect of KIAA1429 knockdown on the migration and invasion of Caki-1 and ACHN cells were detected using a cell wound-healing assay (A) and transwell assay (B). (C) Western blot analysis of vimentin, N-cadherin, and E-cadherin protein expression in Caki-1 and ACHN cells with KIAA1429 knockdown. Data are presented as the means ± SEM. ∗ p < 0.05 by Student’s two-tailed t test.

Article Snippet: KIAA1429 Rabbit Polyclonal antibody , Proteintech , Cat#24761-1-AP.

Techniques: Migration, In Vitro, Knockdown, Wound Healing Assay, Transwell Assay, Western Blot, Expressing, Two Tailed Test

Journal: iScience

Article Title: KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability

doi: 10.1016/j.isci.2026.115198

Figure Lengend Snippet: KIAA1429 promoted tumorigenesis of ccRCC cells in vivo (A) Subcutaneous tumor model of ACHN cells with KIAA1429 knockdown. KIAA1429 knockdown led to decreased tumor volume. (B and C) The changes in volume and weight were measured at the indicated weeks after mice were transplanted with the relevant cells. (D) IHC of vimentin, Ki-67, and E-cadherin protein expression in tumors with KIAA1429 knockdown. Data are presented as the means ± SEM. ∗ p < 0.05, ∗∗∗ p < 0.001 by Student’s two-tailed t test.

Article Snippet: KIAA1429 Rabbit Polyclonal antibody , Proteintech , Cat#24761-1-AP.

Techniques: In Vivo, Knockdown, Expressing, Two Tailed Test

Journal: iScience

Article Title: KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability

doi: 10.1016/j.isci.2026.115198

Figure Lengend Snippet: MYC might be a potential target for regulation by KIAA1429 in ccRCC (A) KIAA1429 has a significant effect on most RNA-specific processes, cell cycle, cell death, apoptosis, and intracellular signaling pathways, as revealed by GO and KEGG analyses. (B) Heatmap illustrating the downregulated genes in ACHN cells after KIAA1429 knockdown. (C) The expression level of MYC in ccRCC, obtained from the TCGA database. (D) Correlation analysis between the expression of MYC and KIAA1429. Data are presented as the means ± SEM. ∗∗∗ p < 0.001 by Student’s two-tailed t test.

Article Snippet: KIAA1429 Rabbit Polyclonal antibody , Proteintech , Cat#24761-1-AP.

Techniques: Protein-Protein interactions, Knockdown, Expressing, Two Tailed Test

Journal: iScience

Article Title: KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability

doi: 10.1016/j.isci.2026.115198

Figure Lengend Snippet: KIAA1429 regulated the expression of MYC mRNA and its stability in an m6A-dependent manner (A and C) KIAA1429 knockdown inhibits the protein and mRNA expression of MYC in ccRCC cells. (B) KIAA1429 knockdown decreased the stability of MYC mRNA. (D) RIP assay showed that KIAA1429 interacts with MYC mRNA in Caki-1 and ACHN cells. (E) KIAA1429 knockdown reduced overall m6A levels in Caki-1 and ACHN cells. (F) KIAA1429 knockdown reduced m6A levels in MYC. (G) m6A methylation sites on MYC were predicted using the SRAMP database. (H) The pmirGLO-MYC-WT or pmirGLO-MYC-MUT luciferase reporter was transfected into KIAA1429-knockdown and control Caki-1 and ACHN cells, and relative luciferase activity was measured. Data are presented as the ratio of firefly to Renilla luciferase activity. Data are presented as the means ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 by Student’s two-tailed t test.

Article Snippet: KIAA1429 Rabbit Polyclonal antibody , Proteintech , Cat#24761-1-AP.

Techniques: Expressing, Knockdown, Methylation, Luciferase, Transfection, Control, Activity Assay, Two Tailed Test

Journal: Translational Cancer Research

Article Title: Identification of immune-related targets of N6-methyladenosine regulators in hepatocellular carcinoma via RNA-seq analysis

doi: 10.21037/tcr-2025-1417

Figure Lengend Snippet: Survival analysis of six m6A regulators. (A–F) OS analysis showing that upregulated expression of IGF2BP2, KIAA1429, METTL3, PRRC2A, RBMX, and ZC3H3 was associated with poor OS in HCC. (G–K) DSS analysis showing that upregulated expression of KIAA1429, METTL3, PRRC2A, RBMX, and ZC3H3 was associated with poor DSS. CI, confidence interval; DSS, disease-specific survival; HCC, hepatocellular carcinoma; HR, hazard ratio; m6A, N6-methyladenosine; OS, overall survival.

Article Snippet: The primary antibodies used were METTL3 (1:500, SANTA, Oregon, USA), KIAA1429 (1:1,000, ABclonal, China), β-actin (1:10,000, ABclonal, China), PRRC2A (1:500, SANTA, Oregon, USA), PD-L1 (1:1,000, ABclonal, China), ZC3H3 (1:500, SANTA, Oregon, USA), STAT3 (1:1,000, CST, USA), RBMX (1:1,000, ABclonal, China), P-STAT3 (1:1,000, CST, USA), AKT (1:1,000, CST, USA), GAPDH (1:10,000, ABclonal, China), p-AKT (1:1,000, CST, USA), and MTOR (1:2,000, Proteintech, Wuhan, China).

Techniques: Expressing

Journal: Translational Cancer Research

Article Title: Identification of immune-related targets of N6-methyladenosine regulators in hepatocellular carcinoma via RNA-seq analysis

doi: 10.21037/tcr-2025-1417

Figure Lengend Snippet: The five m6A regulators that would be correlated with advanced clinical HCC stage and grade. (A) ROC curve analysis was used for estimating HCC tissues and normal tissues in accordance with five m6A regulators expression. (B,C) ROC curve analysis in GSE84402 and GSE45267 . (D-H) The expression of KIAA1429, METTL3, PRRC2A (also known as BAT2), RBMX, and ZC3H3 were detected in stage 1–4 and grade 1–4 (*, P<0.05). AUC, area under curve; HCC, hepatocellular carcinoma; LIHC, liver hepatocellular carcinoma; m6A, N6-methyladenosine; ROC, receiver operating characteristic; TCGA, The Cancer Genome Atlas.

Article Snippet: The primary antibodies used were METTL3 (1:500, SANTA, Oregon, USA), KIAA1429 (1:1,000, ABclonal, China), β-actin (1:10,000, ABclonal, China), PRRC2A (1:500, SANTA, Oregon, USA), PD-L1 (1:1,000, ABclonal, China), ZC3H3 (1:500, SANTA, Oregon, USA), STAT3 (1:1,000, CST, USA), RBMX (1:1,000, ABclonal, China), P-STAT3 (1:1,000, CST, USA), AKT (1:1,000, CST, USA), GAPDH (1:10,000, ABclonal, China), p-AKT (1:1,000, CST, USA), and MTOR (1:2,000, Proteintech, Wuhan, China).

Techniques: Expressing

Journal: Translational Cancer Research

Article Title: Identification of immune-related targets of N6-methyladenosine regulators in hepatocellular carcinoma via RNA-seq analysis

doi: 10.21037/tcr-2025-1417

Figure Lengend Snippet: The top four significantly related drugs in 5 kinds of m6A regulators. (A-E) m6A regulators KIAA1429, METTL3, RBMX, PRRC2A and ZC3H3. IC 50 , half maximal inhibitory concentration; m6A, N6-methyladenosine.

Article Snippet: The primary antibodies used were METTL3 (1:500, SANTA, Oregon, USA), KIAA1429 (1:1,000, ABclonal, China), β-actin (1:10,000, ABclonal, China), PRRC2A (1:500, SANTA, Oregon, USA), PD-L1 (1:1,000, ABclonal, China), ZC3H3 (1:500, SANTA, Oregon, USA), STAT3 (1:1,000, CST, USA), RBMX (1:1,000, ABclonal, China), P-STAT3 (1:1,000, CST, USA), AKT (1:1,000, CST, USA), GAPDH (1:10,000, ABclonal, China), p-AKT (1:1,000, CST, USA), and MTOR (1:2,000, Proteintech, Wuhan, China).

Techniques: Concentration Assay

Journal: Translational Cancer Research

Article Title: Identification of immune-related targets of N6-methyladenosine regulators in hepatocellular carcinoma via RNA-seq analysis

doi: 10.21037/tcr-2025-1417

Figure Lengend Snippet: The PCR and western blot analysis. (A-E) KIAA1429, METTL3, PRRC2A, RBMX and ZC3H3 in three HCC cell lines in PCR analysis. (F-I) The prediction drugs (XAV-939 10 µM and chelerythrine 10 µM) reduced the level of m6A regulators. *, P<0.05. HCC, hepatocellular carcinoma; m6A, N6-methyladenosine; PCR, polymerase chain reaction.

Article Snippet: The primary antibodies used were METTL3 (1:500, SANTA, Oregon, USA), KIAA1429 (1:1,000, ABclonal, China), β-actin (1:10,000, ABclonal, China), PRRC2A (1:500, SANTA, Oregon, USA), PD-L1 (1:1,000, ABclonal, China), ZC3H3 (1:500, SANTA, Oregon, USA), STAT3 (1:1,000, CST, USA), RBMX (1:1,000, ABclonal, China), P-STAT3 (1:1,000, CST, USA), AKT (1:1,000, CST, USA), GAPDH (1:10,000, ABclonal, China), p-AKT (1:1,000, CST, USA), and MTOR (1:2,000, Proteintech, Wuhan, China).

Techniques: Western Blot, Polymerase Chain Reaction

Journal: Scientific Reports

Article Title: KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8 + T cells in colorectal cancer

doi: 10.1038/s41598-025-27586-6

Figure Lengend Snippet: A : Elevated mRNA expression of KIAA1429 in pan-cancer (TCGA database); B : KIAA1429 is highly expressed in CRC tis sues compared to normal tissues (TCGA database, P < 0.001). C : Confirmation of the Figure B results through the GEPIA database( P < 0.05). D : Immunohistochemical staining confirmed higher KIAA1429 expression in CRC tissues compared to adjacent non-tumor tissues (Mann-Whitney U test, P = 2.196e-07); E : High expression of KIAA1429 correlates with poor prognosis (Kaplan-Meier analysis, Log-rank, P = 0.027); F : Nomogram for predicting 1-year survival probability based on clinical factors and KIAA1429 expression. G : Calibration curve assessing nomogram accuracy at 1-year, 3-year, and 5-year time points. H : ROC curve evaluating the diagnostic performance of KIAA1429 expression (AUC = 0.783).

Article Snippet: Afterwards, primary antibodies, including KIAA1429 (25712-1-AP, Proteintech), PD-L1 (28076-1-AP, Proteintech), and CD8 (66868-1-IG, Proteintech), were applied and incubated overnight at 4 °C.

Techniques: Expressing, Immunohistochemical staining, Staining, MANN-WHITNEY, Diagnostic Assay

Journal: Scientific Reports

Article Title: KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8 + T cells in colorectal cancer

doi: 10.1038/s41598-025-27586-6

Figure Lengend Snippet: A : Correlation of KIAA1429 with tumor immune cell infiltration in CRC. B : CD8 + T cells and Treg cells are highly infiltrated with low KIAA1429 expression in CRC (TCGA database, P < 0.01, P < 0.001). C : Expression of KIAA1429 is negatively correlated with the level of CD8 + T cells infiltration in CRC (TCGA database, r =−0.015, P = 0.001). D : Expression of KIAA1429 is negatively correlated with the level of Treg cells infiltration in CRC (TCGA database, r =−0.233, P < 0.001). E : KIAA1429 was negatively correlated with the infiltration of CD8 + T cells and Tregs in both COAD and READ(TCGA database, P < 0.05, P < 0.01); F : Immunohistochemistry showed reduced CD8 + T-cell infiltration in CRC tissues compared to adjacent normal tissues (Spearman’s correlation analysis, r = 0.0995, P = 0.021).

Article Snippet: Afterwards, primary antibodies, including KIAA1429 (25712-1-AP, Proteintech), PD-L1 (28076-1-AP, Proteintech), and CD8 (66868-1-IG, Proteintech), were applied and incubated overnight at 4 °C.

Techniques: Expressing, Immunohistochemistry

Journal: Scientific Reports

Article Title: KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8 + T cells in colorectal cancer

doi: 10.1038/s41598-025-27586-6

Figure Lengend Snippet: A : Protein-protein interaction (PPI) network of KIAA1429 with RNA-related proteins. B : Gene Ontology (GO) enrichment analysis of KIAA1429-related genes. C : SRAMP database predicts a significant m6A binding site on PD-L1 mRNA; D : KIAA1429 shows a positive correlation with PD-L1 expression in CRC tissues(cBioPortal data, P = 2.275e-03); E , F : Immunohistochemistry validated the positive correlation between KIAA1429 and PD-L1 expression in CRC samples (Spearman correlation analysis, P = 1.017e-07); G : Expression levels of KIAA1429 mRNA in various colorectal cancer cell lines, and KIAA1429 is highly expressed in SW620 cells ( P < 0.001); H : siRNA-mediated silencing of KIAA1429 (siKIAA1429-1,−2,−3), with siKIAA1429-2 exhibiting the most effective knockdown( P < 0.01); I : Reduced PD-L1 mRNA expression following KIAA1429 knockdown in SW620 cells ( P < 0.01); J : Western blot analysis confirmed downregulated PD-L1 protein expression in SW620 cells upon KIAA1429 silencing ( P < 0.01).

Article Snippet: Afterwards, primary antibodies, including KIAA1429 (25712-1-AP, Proteintech), PD-L1 (28076-1-AP, Proteintech), and CD8 (66868-1-IG, Proteintech), were applied and incubated overnight at 4 °C.

Techniques: Binding Assay, Expressing, Immunohistochemistry, Knockdown, Western Blot

Journal: Scientific Reports

Article Title: KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8 + T cells in colorectal cancer

doi: 10.1038/s41598-025-27586-6

Figure Lengend Snippet: A : KIAA1429 was knocked down in MC38 and CT26 cells, and the knockdown efficiency was detected by qPCR. B : Representative tumors images in MC38 and CT26 homozygous mice; C : Body weight(left), tumor volume(middle), and tumor weight(right) in MC38 mice( n = 5); D : Body weight(left), tumor volume(middle), and tumor weight(right) in CT26 mice( n = 5); E : Immunohistochemical staining measures the expression of PD-L1 across different groups.

Article Snippet: Afterwards, primary antibodies, including KIAA1429 (25712-1-AP, Proteintech), PD-L1 (28076-1-AP, Proteintech), and CD8 (66868-1-IG, Proteintech), were applied and incubated overnight at 4 °C.

Techniques: Knockdown, Immunohistochemical staining, Staining, Expressing